Xiaozhuo Liu

10PUBLICATIONS
30CO-AUTHORS
Cancer cell biologyPredictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Epigenetics (incl. genome methylation and epigenomics)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Jun 04, 2026
A targetable opioid/cancer associated fibroblast axis drives extracellular matrix remodeling and tumor aggressiveness in pancreatic cancer.

|May 01, 2026
Single-cell imaging analysis, therapeutic modeling and a Phase Ib trial validate BCL-2 as a target across heterogeneous castration-resistant prostate cancer.

|Jul 17, 2025
Cell-resolved high-dimensional imaging analysis, therapeutic modeling, and a Phase Ib clinical study establish BCL-2 as a target across heterogeneous CRPC subtypes.

Anmbreen Jamroze, Xiaozhuo Liu, Surui Hou

|Jul 08, 2025
Loss of ATG5 expression in a subset of human prostate cancers promotes tumor growth through accumulation of p62.

Daric J Wible, Wen Jess Li, Xiaozhuo Liu

|Jun 03, 2025
Increasing Stemness Drives Prostate Cancer Progression, Plasticity, Therapy Resistance and Poor Patient Survival.

Xiaozhuo Liu, Eduardo Cortes, Yibing Ji

|May 02, 2025
Phase Ib Study of Enzalutamide with Venetoclax in Patients with Metastatic Castration-Resistant Prostate Cancer.

Stuthi Perimbeti, Anmbreen Jamroze, Dharmesh Gopalakrishnan

Pageof 2

Frequent Collaborators

6 joint publications

Dean G Tang

5 joint publications

Wen Jess Li

1 joint publications

Joseph A Spernyak

1 joint publications

Ahmed M Abdelaal